- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EVERSANA Announces Real-World Data Agreement with Janssen
Analytic work will drive regulatory grade RWD studies and therapeutic evidence to improve patient outcomes.
EVERSANA today announced an agreement with Janssen Research & Development, LLC (Janssen) to transform clinical data into the much-needed evolution of chronic disease care through real-word data (RWD), data science analysis and regulatory-grade studies. The collaboration between EVERSANA’s RWD Solution team and the Janssen Research & Development Data Science team will help drive evidence-based development of Janssen therapies, treatments, and patient support models.
The agreement will drive a deeper understanding and enhance the design of clinical trials through regulatory-grade, auditable determination of clinical endpoints, thus enabling studies that can reduce clinical trial timelines and offer important signals about how therapies perform in real world settings.
Read more about the new agreement here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
